Lymphoma is a common, devastating cancer that affects thousands of cats every year. Currently, combination chemotherapy is the standard of care. Treatment, however, is both expensive and potentially toxic. L-asparaginase is used in combination with other drugs to treat feline lymphoma. L-asparaginase has excellent potential because it may improve the response to treatment without additional toxicity. This drug is expensive; therefore its efficacy needs to be known to justify its use. This work will provide objective data regarding the value of this drug in cats with lymphoma and will help optimize care for these cancer patients.